In addition to the combination with BET inhibitors, the literature has documented the concurrent application of the CDK9 inhibitor AZD4573 in conjunction with PIM kinase or PI3K inhibitors in the context of diffuse large B-cell lymphoma (DLBCL) and primary lymphoma cells. Here, DNER is linked to diffuse large B-cell lymphoma.